Close

Fujifilm to manufacture bulk substance for ThromboGenics’ eye medication

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

Fujifilm Diosynth Biotechnologies will manufacture the bulk substance for ThromboGenics’ FDA approved Jetrea (ocriplasmin) indicated for symptomatic vitreomacular adhesion (VMA).

The companies signed a long-term supply agreement in September 2010 and worked towards completing validation and setting up a well characterised procedure.

Fujifilm Diosynth Biotechnologies’ Billingham managing director Steve Bagshaw said, “This is fifth licensed biopharmaceutical manufactured by Fujifilm Diosynth Biotechnologies and the second made at our Billingham site, demonstrating our growing expertise in helping to transition biopharmaceuticals from the clinic to become marketed new drugs”.

Jetrea is an enzyme that breaks down proteins that lead to VMA in the eye. The protein breakdown results in enhanced separation between the vitreous and macula and minimizes the probability of tugging.

ThromboGenics CEO Dr. Patrik De Haes said, “Fujifilm Diosynth Biotechnologies has been a key partner in helping to bring our first drug to market. Their team at Billingham have done an excellent job in developing and validating a robust process and manufacturing material to enable us to launch the product on schedule.”

 

Latest stories

Related stories

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back